About Alzheimer’s Treatment Center

Leqembi (Lecanemab) infusions are a promising new treatment option to slow down the cognitive and functional decline associated with Alzheimer’s disease. Leqembi treatment is a targeted approach to reduce the accumulation of amyloid beta protein, which research has shown to play a critical role in the onset and progression of Alzheimer’s disease. By reducing the accumulation of amyloid plaques in the brain, this medication and others like it delay cognitive decline in individuals with Alzheimer’s disease. This translates to better quality of life for both patients, families, and caregivers.

Leqembi is an antibody therapy designed to target the amyloid beta protein, which contributes to the development and progression of Alzheimer’s disease. By binding to and clearing amyloid plaques from the brain, Leqembi slows down the progression of the disease.